SCHEMBL4019686

SCHEMBL4019686

Cc1cccc2c1-c1c(C)cccc1C2=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
MAPK1 P28482 4/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
L3MBTL1 Q9Y468 3/20 0.55
TSHR P16473 2/20 0.55
RAB9A P51151 2/20 0.55
NPC1 O15118 1/20 0.55
CYP3A4 P08684 1/20 0.55
CASP3 P42574 1/20 0.55
HBB P68871 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
ADORA2A P29274 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA7 P43166 1/20 0.52
CA9 Q16790 1/20 0.52
MAPT P10636 3/20 0.50
TDP1 Q9NUW8 3/20 0.50
ELANE P08246 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6036681 0.95 TDP2 (0.52) ALDH1A1MAPK1SMN1; SMN2L3MBTL1TSHR
SCHEMBL12258322 0.92 ALDH1A1 (0.54) ALDH1A1MAPK1SMN1; SMN2L3MBTL1TSHR
SCHEMBL1688847 0.90 ALDH1A1 (0.55) ALDH1A1MAPK1SMN1; SMN2L3MBTL1TSHR
SCHEMBL2605006 0.88 ALDH1A1 (0.60) ALDH1A1MAPK1SMN1; SMN2L3MBTL1TSHR
SCHEMBL30580334 0.88 ALDH1A1 (0.66) ALDH1A1MAPK1SMN1; SMN2L3MBTL1TSHR
SCHEMBL224650 0.88 ALDH1A1 (0.66) ALDH1A1MAPK1SMN1; SMN2L3MBTL1TSHR
SCHEMBL29392682 0.88 ALDH1A1 (0.60) ALDH1A1MAPK1SMN1; SMN2L3MBTL1TSHR
SCHEMBL10885948 0.85 ELANE (0.57) ALDH1A1MAPK1SMN1; SMN2L3MBTL1TSHR
SCHEMBL29634210 0.84 CA1 (0.52) ALDH1A1MAPK1SMN1; SMN2L3MBTL1TSHR
SCHEMBL4161497 0.84 CA1 (0.52) ALDH1A1MAPK1SMN1; SMN2L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10550209-B2 Catalysts for producing polymers and enhanced properties EXXONMOBIL CHEMICAL PATENTS INC. (US) 2020-02-04 US disclosed
US-10550209-B2 Catalysts for producing polymers and enhanced properties EXXONMOBIL CHEMICAL PATENTS INC. (US) 2020-02-04 US disclosed
US-20180244816-A1 Catalysts for Producing Polymers and Enhanced Properties EXXONMOBIL CHEMICAL PATENTS INC. 2018-08-30 US disclosed
US-9988471-B2 Catalysts for producing polymers with enhanced properties EXXONMOBIL CHEMICAL PATENTS INC (US) 2018-06-05 US disclosed
US-9988471-B2 Catalysts for producing polymers with enhanced properties EXXONMOBIL CHEMICAL PATENTS INC (US) 2018-06-05 US disclosed
US-9988471-B2 Catalysts for producing polymers with enhanced properties EXXONMOBIL CHEMICAL PATENTS INC (US) 2018-06-05 US disclosed
US-20170174798-A1 Catalysts for Producing Polymers with Enhanced Properties EXXONMOBIL CHEMICAL PATENTS INC. 2017-06-22 US disclosed
US-20170174798-A1 Catalysts for Producing Polymers with Enhanced Properties EXXONMOBIL CHEMICAL PATENTS INC. 2017-06-22 US disclosed
WO-2017105635-A1 CATALYSTS FOR PRODUCING POLYMERS WITH ENHANCED PROPERTIES EXXONMOBIL CHEMICAL PATENTS INC. (US) 2017-06-22 WO disclosed
WO-2017105635-A1 CATALYSTS FOR PRODUCING POLYMERS WITH ENHANCED PROPERTIES EXXONMOBIL CHEMICAL PATENTS INC. (US) 2017-06-22 WO disclosed
EP-2061755-A1 TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2009-05-27 EP disclosed
US-20090069408-A1 TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2009-03-12 US disclosed
WO-2008109840-A1 TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS XENON PHARMACEUTICALS INC. (CA) 2008-09-12 WO disclosed
EP-0666267-B1 Organometallic fluorenyl compounds, preparation, and use PHILLIPS PETROLEUM CO (US) 2001-04-18 EP disclosed
US-5571880-A CATALYSTS FOR POLYMERIZATION OF OLEFINS ESPECIALLY TO OBTAIN SYNDIOTACTIC POLYMERS PHILLIPS PETROLEUM COMPANY (US) 1996-11-05 US disclosed
EP-0666267-A2 Organometallic fluorenyl compounds, preparation, and use PHILLIPS PETROLEUM COMPANY (US) 1995-08-09 EP disclosed
EP-0531443-A4 METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN 1993-04-21 EP disclosed
EP-0531443-A1 METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN NOVA PHARMACEUTICAL CORPORATION (US) 1993-03-17 EP disclosed
US-5079260-A Side effect reduction; fluorene derivatives NOVA PHARMACEUTICAL CORPORATION (US) 1992-01-07 US disclosed
WO-1991018596-A1 METHODS FOR TREATING INFLAMMATION AND COMPOUNDS AND COMPOSITIONS SUITABLE FOR USE THEREIN WEITZBERG MOSHE (US) 1991-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069408-A1 TRICYCLIC COMPOUNDS USEFUL IN TREATING IRON DISORDERS TFRC, SLC40A1, FECH ALDH1A1 1638/4885MAPK1 4346/4885SMN1; SMN2 1475/4885
US-10550209-B2 Catalysts for producing polymers and enhanced properties PUF60, DBF4, PARN ALDH1A1 2010/4885MAPK1 3980/4885SMN1; SMN2 2975/4885
US-20180244816-A1 Catalysts for Producing Polymers and Enhanced Properties PUF60, DBF4, PARN ALDH1A1 2010/4885MAPK1 3980/4885SMN1; SMN2 2975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.